Aligos Therapeutics, Inc. ALGS 深 沪
已收盘 02-06 16:00:00 美东时间
7.32
+0.830
+12.79%
华盛通- 最 高7.465
- 今 开6.70
- 成交量 7.81万股
- 最 低 6.70
- 昨 收 6.49
- 总市值 4504.42万
- 52周最高 24.325
- 市盈率 静 --
- 换手率 1.27%
- 52周最低 3.76
- 委 比 -46.22%
- 总股本 615.36万
- 历史最高 937.75
- 量 比 1.28
- 振 幅 11.79%
- 历史最低 3.76
- 每 手 1
- 风险率 4.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20
UBS analyst Michael Yee initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $20.
01-08 04:13
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
2025-12-18 20:05
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics granted 14,100 non-qualified stock options to newly hired employees under its 2024 Inducement Plan on December 9, 2025. The options have an exercise price equal to the closing stock price on the grant date and vest over four years, with 25% vesting after the first year and the rest in monthly installments. The company, focused on developing therapies for liver and viral diseases, uses the plan exclusively for new hires not pre...
2025-12-12 13:00
Aligos Therapeutics Announces Data From Four Presentations, Including Two Oral Presentations, At HEP-DART 2025 Meeting
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from
2025-12-11 21:11
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics granted 23,600 non-qualified stock options to newly hired employees on November 11, 2025, under its 2024 Inducement Plan. The options have an exercise price based on the stock's closing price on the grant date and vest over four years, with 25% vesting after the first year and the remainder vesting monthly. Aligos, a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and viral diseases.
2025-11-14 13:00
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
Aligos Therapeutics announced positive data for pevifoscorvir sodium at the AASLD 2025 meeting, highlighting its best-in-class potential for treating chronic hepatitis B. The oral and poster presentations showed sustained viral suppression, with 75% of HBeAg+ and 100% of HBeAg- subjects maintaining HBV DNA below the lower limit of quantification during NA monotherapy. Pevifoscorvir sodium's ability to reduce HBV antigen and RNA levels, along with...
2025-11-10 13:00
Aligos Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.
Aligos Therapeutics shares are trading lower after the company reported worse-t...
2025-11-06 23:59
Aligos Therapeutics Q3 EPS $(3.04) Misses $(2.27) Estimate, Sales $741.000K Beat $500.000K Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(3.04) per share which missed the analyst consensus estimate of $(2.27) by 34.22 percent. This is a 0.98 percent increase over losses of $(3.07) per share
2025-11-06 21:31
Aligos Therapeutics to Present at Upcoming Investor Conferences
Aligos Therapeutics announced that its management will participate in two upcoming investor conferences: the Jefferies London Healthcare Conference on November 17, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. Both events will feature fireside chats, which can be accessed via Aligos’ website.
2025-11-04 13:30
